| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| VMDViemed Healthcare, Inc. | 286.66M | 7.54 | 26.93 | 22.54% | 5.34% | 10.05% | 0.46% | 0.05 |
| VVOSVivos Therapeutics, Inc. | 20.2M | 2.14 | -0.96 | 8.91% | -98.77% | -6.76% | 0.19 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 3.79M | 11.39M | 13.07M | 16.89M | 16.02M | 13.8M | 15.03M |
| Revenue Growth % | - | 2% | 0.15% | 0.29% | -0.05% | -0.14% | 0.09% |
| Cost of Goods Sold | 1.08M | 2.74M | 2.65M | 4.28M | 6M | 5.53M | 6.01M |
| COGS % of Revenue | 0.29% | 0.24% | 0.2% | 0.25% | 0.37% | 0.4% | 0.4% |
| Gross Profit | 2.71M | 8.66M | 10.41M | 12.6M | 10.02M | 8.27M | 9.02M |
| Gross Margin % | 0.71% | 0.76% | 0.8% | 0.75% | 0.63% | 0.6% | 0.6% |
| Gross Profit Growth % | - | 2.19% | 0.2% | 0.21% | -0.21% | -0.17% | 0.09% |
| Operating Expenses | 11.05M | 19.23M | 19.12M | 32.08M | 35.05M | 25.57M | 20.19M |
| OpEx % of Revenue | 2.91% | 1.69% | 1.46% | 1.9% | 2.19% | 1.85% | 1.34% |
| Selling, General & Admin | 10.44M | 18.48M | 18.4M | 31.34M | 34.38M | 24.85M | 19.61M |
| SG&A % of Revenue | 2.75% | 1.62% | 1.41% | 1.86% | 2.15% | 1.8% | 1.3% |
| Research & Development | 0 | 0 | 0 | 0 | 200K | 100K | 0 |
| R&D % of Revenue | - | - | - | - | 0.01% | 0.01% | - |
| Other Operating Expenses | 610.67K | 751.23K | 717.87K | 733K | 469K | 621K | 581K |
| Operating Income | -8.34M | -10.58M | -8.71M | -19.47M | -25.03M | -17.3M | -11.17M |
| Operating Margin % | -2.2% | -0.93% | -0.67% | -1.15% | -1.56% | -1.25% | -0.74% |
| Operating Income Growth % | - | -0.27% | 0.18% | -1.24% | -0.29% | 0.31% | 0.35% |
| EBITDA | -7.73M | -9.83M | -7.99M | -18.74M | -24.36M | -16.68M | -10.59M |
| EBITDA Margin % | -2.04% | -0.86% | -0.61% | -1.11% | -1.52% | -1.21% | -0.7% |
| EBITDA Growth % | - | -0.27% | 0.19% | -1.34% | -0.3% | 0.32% | 0.36% |
| D&A (Non-Cash Add-back) | 610.67K | 751.23K | 717.87K | 733K | 669K | 621K | 581K |
| EBIT | -8.34M | -10.62M | -11.96M | -20.27M | -25.03M | -17.3M | -11.17M |
| Net Interest Income | -102.97K | -116.74K | -17K | 103K | 89K | 0 | 0 |
| Interest Income | 0 | 21.13K | 79.61K | 117K | 89K | 0 | 0 |
| Interest Expense | 102.97K | 137.88K | 96.68K | 14K | 0 | 0 | 0 |
| Other Income/Expense | -102.97K | -177.09K | -3.35M | 94K | 1.19M | 3.71M | 35K |
| Pretax Income | -8.44M | -10.75M | -12.06M | -20.29M | -23.84M | -13.58M | -11.14M |
| Pretax Margin % | -2.23% | -0.94% | -0.92% | -1.2% | -1.49% | -0.98% | -0.74% |
| Income Tax | 102.97K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1.01% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -8.54M | -10.75M | -12.06M | -20.29M | -23.84M | -13.58M | -11.14M |
| Net Margin % | -2.25% | -0.94% | -0.92% | -1.2% | -1.49% | -0.98% | -0.74% |
| Net Income Growth % | - | -0.26% | -0.12% | -0.68% | -0.18% | 0.43% | 0.18% |
| Net Income (Continuing) | -8.44M | -10.75M | -12.06M | -20.29M | -23.84M | -13.58M | -11.14M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -18.49 | -21.94 | -24.70 | -23.89 | -25.90 | -11.14 | -2.22 |
| EPS Growth % | - | -0.19% | -0.13% | 0.03% | -0.08% | 0.57% | 0.8% |
| EPS (Basic) | -18.49 | -21.94 | -24.70 | -23.89 | -25.90 | -11.14 | -2.22 |
| Diluted Shares Outstanding | 461.93K | 496.43K | 728.38K | 849.32K | 920.48K | 1.22M | 5.02M |
| Basic Shares Outstanding | 461.93K | 496.43K | 728.38K | 849.32K | 920.48K | 1.22M | 5.02M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.01M | 1.98M | 20.39M | 27.32M | 5.42M | 2.46M | 7.47M |
| Cash & Short-Term Investments | 1.25M | 469.35K | 18.21M | 24.03M | 3.52M | 1.64M | 6.26M |
| Cash Only | 1.25M | 469.35K | 18.21M | 24.03M | 3.52M | 1.64M | 6.26M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 595.19K | 955.99K | 1.52M | 1.72M | 457K | 202K | 430K |
| Days Sales Outstanding | 57.29 | 30.63 | 42.34 | 37.16 | 10.41 | 5.34 | 10.44 |
| Inventory | 0 | 263.81K | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | 35.19 | - | - | - | - | - |
| Other Current Assets | 133.93K | 0 | 61 | 0 | 1.45M | 0 | 783K |
| Total Non-Current Assets | 6.19M | 5.57M | 4.93M | 6.37M | 8.3M | 8.27M | 7.81M |
| Property, Plant & Equipment | 1.28M | 1.14M | 871.6K | 2.83M | 4.78M | 4.7M | 4.38M |
| Fixed Asset Turnover | 2.96x | 10.00x | 14.99x | 5.98x | 3.35x | 2.94x | 3.43x |
| Goodwill | 3.74M | 2.67M | 2.67M | 2.84M | 2.84M | 2.84M | 2.84M |
| Intangible Assets | 1.14M | 689.15K | 270.12K | 341K | 302K | 420K | 370K |
| Long-Term Investments | 0 | 785.06K | 810.63K | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 26.91K | 1.07M | 1.12M | 356K | 374K | 307K | 216K |
| Total Assets | 8.2M | 7.55M | 25.33M | 33.69M | 13.72M | 10.73M | 15.28M |
| Asset Turnover | 0.46x | 1.51x | 0.52x | 0.50x | 1.17x | 1.29x | 0.98x |
| Asset Growth % | - | -0.08% | 2.35% | 0.33% | -0.59% | -0.22% | 0.42% |
| Total Current Liabilities | 2.16M | 9.09M | 7.82M | 7.51M | 6.81M | 7.29M | 4.98M |
| Accounts Payable | 474.08K | 1.08M | 781K | 920K | 1.41M | 2.15M | 1.1M |
| Days Payables Outstanding | 159.98 | 144.53 | 107.43 | 78.44 | 85.76 | 141.58 | 66.66 |
| Short-Term Debt | 161.54K | 3.71M | 866.97K | 1.26M | 419K | 474K | 0 |
| Deferred Revenue (Current) | 889.51K | 1000K | 1000K | 1000K | 1000K | 1000K | 896K |
| Other Current Liabilities | 0 | 0 | 85 | 1.46M | 280K | 560K | 273K |
| Current Ratio | 0.93x | 0.22x | 2.61x | 3.64x | 0.80x | 0.34x | 1.50x |
| Quick Ratio | 0.93x | 0.19x | 2.61x | 3.64x | 0.80x | 0.34x | 1.50x |
| Cash Conversion Cycle | - | -78.71 | - | - | - | - | - |
| Total Non-Current Liabilities | 1.22M | 1.4M | 587.06K | 641K | 2.11M | 3.03M | 2.35M |
| Long-Term Debt | 525K | 0 | 423.1K | 298K | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 1.99M | 1.52M | 1.03M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | -112K | 0 | 0 |
| Other Non-Current Liabilities | 695.02K | 1.4M | 146K | 343K | 112K | 1.22M | 1.22M |
| Total Liabilities | 3.38M | 10.49M | 8.41M | 8.15M | 8.92M | 10.32M | 7.33M |
| Total Debt | 686.54K | 3.71M | 1.29M | 1.63M | 2.41M | 2M | 1.51M |
| Net Debt | -568.18K | 3.24M | -16.92M | -22.4M | -1.11M | 352K | -4.75M |
| Debt / Equity | 0.14x | - | 0.08x | 0.06x | 0.50x | 4.85x | 0.19x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -80.95x | -76.72x | -90.08x | -1390.79x | - | - | - |
| Total Equity | 4.83M | -2.94M | 16.92M | 25.54M | 4.8M | 411K | 7.95M |
| Equity Growth % | - | -1.61% | 6.75% | 0.51% | -0.81% | -0.91% | 18.35% |
| Book Value per Share | 10.45 | -5.93 | 23.23 | 30.07 | 5.22 | 0.34 | 1.58 |
| Total Shareholders' Equity | 4.83M | -2.94M | 16.92M | 25.54M | 4.8M | 411K | 7.95M |
| Common Stock | 1.21K | 1.24K | 2K | 2K | 2K | 0 | 0 |
| Retained Earnings | -12.52M | -23.28M | -35.33M | -55.62M | -79.47M | -93.05M | -104.19M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -666.67K | -1.32M | -1.5M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -5.31M | -5.34M | -5.68M | -15.73M | -19.59M | -11.95M | -12.69M |
| Operating CF Margin % | -1.4% | -0.47% | -0.43% | -0.93% | -1.22% | -0.87% | -0.84% |
| Operating CF Growth % | - | -0.01% | -0.06% | -1.77% | -0.24% | 0.39% | -0.06% |
| Net Income | -8.44M | -10.75M | -12.06M | -20.29M | -23.84M | -13.58M | -11.14M |
| Depreciation & Amortization | 610.67K | 751.23K | 717.87K | 733K | 669K | 621K | 581K |
| Stock-Based Compensation | 1.28M | 1.99M | 2.17M | 2.66M | 2.4M | 924K | 762K |
| Deferred Taxes | 0 | 60.34K | 0 | 1.14M | 0 | 0 | 0 |
| Other Non-Cash Items | 364.34K | 83.07K | 3.92M | -9K | -518K | -2.77M | 42K |
| Working Capital Changes | 867.1K | 2.53M | -431.07K | 28K | 1.71M | 2.86M | -2.94M |
| Change in Receivables | -530.29K | -276.1K | -559.6K | 228K | 746K | 255K | -228K |
| Change in Inventory | 0 | 401.01K | 332.59K | 168K | 0 | 0 | 0 |
| Change in Payables | 246.53K | 547.62K | -274.21K | 139K | 491K | 734K | -1.05M |
| Cash from Investing | -1.12M | 86.22K | -120.25K | -2.61M | -924K | -853K | -568K |
| Capital Expenditures | -1.25M | -175.6K | -120.25K | -2.4M | -924K | -853K | -568K |
| CapEx % of Revenue | 0.33% | 0.02% | 0.01% | 0.14% | 0.06% | 0.06% | 0.04% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 11.82K | 0 | 13K | 0 | 0 | 0 |
| Cash from Financing | 5.25M | 4.47M | 23.54M | 24.17M | 0 | 10.92M | 17.88M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | -12.46K | 738.61K | -245.14K | -2.24M | 0 | 0 | 10.08M |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -6.56M | -5.52M | -5.8M | -18.13M | -20.51M | -12.75M | -13.26M |
| FCF Margin % | -1.73% | -0.48% | -0.44% | -1.07% | -1.28% | -0.92% | -0.88% |
| FCF Growth % | - | 0.16% | -0.05% | -2.13% | -0.13% | 0.38% | -0.04% |
| FCF per Share | -14.21 | -11.11 | -7.96 | -21.35 | -22.28 | -10.46 | -2.64 |
| FCF Conversion (FCF/Net Income) | 0.62x | 0.50x | 0.47x | 0.78x | 0.82x | 0.88x | 1.14x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -176.97% | -1141.81% | -172.56% | -95.59% | -157.19% | -521.22% | -266.25% |
| Return on Invested Capital (ROIC) | -146.81% | -348.26% | -4370.87% | -929.33% | -549.25% | -581.97% | -422.18% |
| Gross Margin | 71.48% | 75.99% | 79.69% | 74.65% | 62.52% | 59.93% | 60% |
| Net Margin | -225.25% | -94.39% | -92.28% | -120.18% | -148.81% | -98.42% | -74.09% |
| Debt / Equity | 0.14x | - | 0.08x | 0.06x | 0.50x | 4.85x | 0.19x |
| Interest Coverage | -80.95x | -76.72x | -90.08x | -1390.79x | - | - | - |
| FCF Conversion | 0.62x | 0.50x | 0.47x | 0.78x | 0.82x | 0.88x | 1.14x |
| Revenue Growth | - | 200.43% | 14.68% | 29.23% | -5.1% | -13.87% | 8.91% |
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Product | - | - | - | - | 7.87M |
| Product Growth | - | - | - | - | - |
| Service | - | - | - | - | 7.16M |
| Service Growth | - | - | - | - | - |
| Appliances | - | - | - | - | 5.6M |
| Appliances Growth | - | - | - | - | - |
| VIP | - | - | - | - | 2.48M |
| VIP Growth | - | - | - | - | - |
| Sponsorship Seminar Other | - | - | - | - | 1.94M |
| Sponsorship Seminar Other Growth | - | - | - | - | - |
| Billing Intelligence Services | - | - | - | - | 840K |
| Billing Intelligence Services Growth | - | - | - | - | - |
| Center Revenue | 341.96K | 480K | 561K | 189K | - |
| Center Revenue Growth | - | 40.37% | 16.88% | -66.31% | - |
| Management Service Revenue | - | 313K | 63K | - | - |
| Management Service Revenue Growth | - | - | -79.87% | - | - |
Vivos Therapeutics, Inc. (VVOS) reported $17.3M in revenue for fiscal year 2024. This represents a 357% increase from $3.8M in 2018.
Vivos Therapeutics, Inc. (VVOS) grew revenue by 8.9% over the past year. This is steady growth.
Vivos Therapeutics, Inc. (VVOS) reported a net loss of $17.1M for fiscal year 2024.
Vivos Therapeutics, Inc. (VVOS) has a return on equity (ROE) of -266.3%. Negative ROE indicates the company is unprofitable.
Vivos Therapeutics, Inc. (VVOS) had negative free cash flow of $14.4M in fiscal year 2024, likely due to heavy capital investments.